<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202017000300312</article-id>
<article-id pub-id-type="doi">10.29277/ruc/32.3.12</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento farmacológico de la insuficiencia cardíaca. ¿Qué hay de nuevo?]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacological management of heart failure: what is new?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[Michel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pierre y Marie Curie - ICAN - Hospital Pitié-Salpêtrière Departamento de Cardiología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>312</fpage>
<lpage>320</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202017000300312&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202017000300312&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202017000300312&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El manejo de la insuficiencia cardíaca crónica con fracción de eyección reducida (ICFEr) ha cambiado considerablemente en los últimos 30 años: la introducción de inhibidores de la enzima convertidora de angiotensina (IECA), bloqueadores beta (BB), antagonistas de los receptores de la angiotensina (ARAII), antagonistas de los receptores de los mineralocorticoides (ARM) y del bloqueador de canales If (BCI), ivabradina, han llevado a una reducción significativa en la mortalidad y en la mortalidad por insuficiencia cardíaca (IC). Recientemente, un ensayo que prueba un doble inhibidor que bloquea el receptor de angiotensina II y la neprilisina, la enzima responsable de la degradación del péptido natriurético tipo B, mostró que esta molécula compleja mejoró los resultados clínicos en comparación con el IECA enalapril. Sin embargo, persisten retos en en el manejo de esta condición: un cumplimiento subóptimo de las recomendaciones de las guías, un perfil cambiante de pacientes con IC que son mayores y tienen múltiples comorbilidades y una alta tasa de rehospitalizaciones tempranas. La insuficiencia cardíaca con fracción de eyección preservada (ICFEp), que constituye una proporción significativa de la población con IC, sigue siendo un dilema clínico; ninguna intervención farmacológica ha demostrado hasta el momento resultados beneficiosos convincentes. La heterogeneidad de las poblaciones ensayadas, el papel de las comorbilidades, las dificultades para identificar a los pacientes con ICFEp, así como un desajuste entre los fenotipos clínicos y los tratamientos probados son posibles explicaciones del fracaso en encontrar intervenciones beneficiosas. En general, el manejo de la IC después del alta sigue siendo fragmentado y se requieren acciones concertadas de todos los profesionales involucrados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary The management of chronic heart failure with low ejection fraction has changed considerably over the last thirty years: the introduction of angiotensin converting enzyme inhibitors, beta-blockers, angiotensin receptor blockers, mineralocorticoid receptor antagonists and of the ivabradine If blocker has led to a significant reduction in mortality and in heart failure mortality in this condition. More recently, a trial testing a dual inhibitor blocking the angiotensin-II receptor and neprylisin, the enzyme responsible for B type natriuretic peptide degradation showed that this complex molecule improved clinical outcomes compared to the ACE-inhibitor enalapril. However, challenges persist in the management of this condition with a suboptimal implementation of guidelines recommended therapies, a changing profile of heart failure patients who are older and have multiple comorbidities and a high rate of early rehospitalizations for heart failure. Heart failure with preserved ejection fraction, a significant proportion of the heart failure population, remains a clinical dilemma: no pharmacological intervention has so far demonstrated any convincing benefit on outcomes. Heterogeneity of the populations tested, role of comorbidities, difficulties in identifying patients with HFpEF as well as a mismatch between the clinical phenotypes and the treatments tested are potential explanations of the failure to find beneficial interventions. Overall the management of heart failure after discharge remains fragmented and concerted actions of all professionals concerned are needed.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insuficiencia cardíaca]]></kwd>
<kwd lng="es"><![CDATA[Farmacología]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Pharmacology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Consensus Trial Study Group</collab>
<article-title xml:lang=""><![CDATA[Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1987</year>
<volume>316</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1429-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SOLVD Investigators]]></surname>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Hood]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1991</year>
<volume>325</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1995</year>
<volume>273</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1450-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flather]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction a systematic overview of data from individual patients]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>355</volume>
<numero>9215</numero>
<issue>9215</issue>
<page-range>1575-81</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2016</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>891-975</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bristow]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Colucci]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1996</year>
<volume>334</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1349-55</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>CIBIS-II Investigators and Committees</collab>
<article-title xml:lang=""><![CDATA[The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<numero>9146</numero>
<issue>9146</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wedel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Waagstein]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2000</year>
<volume>283</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1295-302</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Roecker]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Mohacsi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rouleau]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Tendera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of initiating carvedilol in patients with severe chronic heart failure results from the COPERNICUS Study]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>289</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>712-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flather]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Shibata]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Parkhomenko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borbola]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2005</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>215-25</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castaigne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>709-17</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eplerenone in patients with systolic heart failure and mild symptoms]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Held]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Michelson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Olofsson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors the CHARM-Alternative trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9386</numero>
<issue>9386</issue>
<page-range>772-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gottlieb]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tognoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1414-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ostergren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Held]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Michelson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors the CHARM-Added trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9386</numero>
<issue>9386</issue>
<page-range>767-71</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borer]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dubost-Brama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivabradine and outcomes in chronic heart failure (SHIFT) a randomised placebo-controlled study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<numero>9744</numero>
<issue>9744</issue>
<page-range>875-85</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ekman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chassany]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borer]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure results from the SHIFT study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2395-404</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function results from the SHIFT echocardiography substudy]]></article-title>
<collab>O'Meara E.Komajda M.Böhm M.Borer JS.Ford I</collab>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2507-15</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lefkowitz]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Rizkala]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin-neprilysin inhibition versus enalapril in heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>993-1004</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laribi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aouba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolaou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lassus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Solal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Plaisance]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in death attributed to heart failure over the past two decades in Europe]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2012</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>234-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlström]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chioncel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Leiro]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Drozdz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EURObservational Research Programme the Heart Failure Pilot Survey (ESC-HF Pilot)]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2010</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1076-84</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krumholz]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Normand]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>130</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>966-75</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ekman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ekman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Odén]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosengren]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population impact of heart failure and the most common forms of cancer a study of 1 162 309 hospital cases in Sweden (1988 to 2004)]]></article-title>
<source><![CDATA[Circ Cardiovasc Qual Outcomes]]></source>
<year>2010</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>573-80</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pocock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Skali]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>116</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1482-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Blair]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Konstam]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Wedge]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bahit]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2010</year>
<volume>159</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>841-849.e1</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jencks]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rehospitalizations among patients in the Medicare fee-for-service program]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>360</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1418-28</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Sahay]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kapoor]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Pham]]></surname>
<given-names><![CDATA[MX]]></given-names>
</name>
<name>
<surname><![CDATA[Massie]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>362-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Trogdon]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Khavjou]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dracup]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Forecasting the future of cardiovascular disease in the United States a policy statement from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>933-44</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holcomb]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dickstein]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale for and design of the TRUE-AHF trial the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>673-81</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teerlink]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serelaxin in addition to standard therapy in acute heart failure rationale and design of the RELAX-AHF-2 study]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>800-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen Solal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leurs]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Assyag]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Beauvais]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Clerson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Contre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction the FUTURE survey]]></article-title>
<source><![CDATA[Arch Cardiovasc Dis]]></source>
<year>2012</year>
<volume>105</volume>
<numero>6-7</numero>
<issue>6-7</issue>
<page-range>355-65</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Troughton]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Frampton]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner-La Rocca]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Pfisterer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eurlings]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[Erntell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization an individual patient meta-analysis]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1559-67</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inglis]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[McAlister]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which components of heart failure programmes are effective A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2011</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1028-40</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Tendera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adamus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Freemantle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Polonski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The perindopril in elderly people with chronic heart failure (PEP-CHF) study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2006</year>
<volume>27</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2338-45</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Held]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction the CHARM-Preserved Trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9386</numero>
<issue>9386</issue>
<page-range>777-81</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massie]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Carson]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McKelvie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zile]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Irbesartan in patients with heart failure and preserved ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>359</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2456-67</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Assmann]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Boineau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Claggett]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spironolactone for heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1383-92</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakata]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shiba]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Miyata]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nochioka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Miura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
<volume>36</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>915-23</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owan]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Hodge]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Herges]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobsen]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in prevalence and outcome of heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>251-9</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How do patients with heart failure with preserved ejection fraction die]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2013</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>604-13</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonarow]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Stough]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Gheorghiade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure a report from the OPTIMIZE-HF Registry]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2007</year>
<volume>50</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>768-77</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zile]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Gaasch]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Haass]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Little]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mode of death in patients with heart failure and a preserved ejection fraction results from the Irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>121</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1393-405</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Jhund]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Castagno]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>60</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2349-56</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction no laughing matter]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>62</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1339-42</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guazzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vicenzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arena]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guazzi]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary hypertension in heart failure with preserved ejection fraction a target of phosphodiesterase-5 inhibition in a 1-year study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>124</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>164-74</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Borlaug]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Semigran]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>309</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1268-77</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pieske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CSP]]></given-names>
</name>
<name>
<surname><![CDATA[Pieske-Kraigher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction results of the SOluble guanylate Cyclase stimulatoR in heart failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2017</year>
<volume>38</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1119-27</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isnard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Solal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pieske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Zile]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pieske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kraigher-Krainer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction a phase 2 double-blind randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9851</numero>
<issue>9851</issue>
<page-range>1387-95</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure with preserved ejection fraction a clinical dilemma]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1022-32</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
